Advertisement

Research Article Free access | 10.1172/JCI115579

An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.

M Andrew, L Mitchell, L Berry, B Paes, M Delorme, F Ofosu, R Burrows, and B Khambalia

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.

Find articles by Andrew, M. in: PubMed | Google Scholar

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.

Find articles by Mitchell, L. in: PubMed | Google Scholar

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.

Find articles by Berry, L. in: PubMed | Google Scholar

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.

Find articles by Paes, B. in: PubMed | Google Scholar

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.

Find articles by Delorme, M. in: PubMed | Google Scholar

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.

Find articles by Ofosu, F. in: PubMed | Google Scholar

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.

Find articles by Burrows, R. in: PubMed | Google Scholar

Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.

Find articles by Khambalia, B. in: PubMed | Google Scholar

Published January 1, 1992 - More info

Published in Volume 89, Issue 1 on January 1, 1992
J Clin Invest. 1992;89(1):321–326. https://doi.org/10.1172/JCI115579.
© 1992 The American Society for Clinical Investigation
Published January 1, 1992 - Version history
View PDF
Abstract

Investigation of the in vitro ability of plasma from pregnant women to inhibit exogenous thrombin (25 nM) demonstrated that heparin cofactor II inhibited more thrombin (3.0 +/- 0.7 nM, mean +/- SD) than plasma from women 3-5 d postpartum (1.9 +/- 0.5 nM) or plasma from nonpregnant adults (1.5 +/- 0.4 nM). Levels of heparin cofactor II were only slightly increased over normal in both pregnant and postpartum women and did not account for the observed increase in thrombin bound to heparin cofactor II. Assay of pregnancy plasma for dermatan sulfate anticoagulant activity demonstrated the presence of activity equivalent to 0.23 +/- 0.02 micrograms/ml of porcine mucosal dermatan sulfate. This activity could not be demonstrated in normal adult plasma or plasma from women on the contraceptive pill. The mass of dermatan sulfate in pregnancy and umbilical cord plasmas was increased over adult control plasma by 0.20 micrograms/ml (53%) and 0.29 micrograms/ml (76%), respectively. The glycosaminoglycan-containing fraction of plasma was isolated and an assay for anticoagulant dermatan sulfate confirmed its presence in both pregnancy and cord plasmas but minimal activity in adult plasma. Gel chromatography of isolated fractions from both pregnancy and cord plasmas revealed a polydisperse, active species with apparent Mr 150,000 D. Reductive elimination decreased the apparent Mr of the active species on gel chromatography to 31,000 D for cord and 21,000 D for pregnancy products. This confirmed the presence of an anticoagulant active dermatan sulfate proteoglycan circulating in the plasmas of pregnant women at term and fetuses at delivery.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (January 1, 1992): No description
Advertisement
Advertisement